[1] |
Haggar FA, Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg, 2009, 22(4): 191-197.
|
[2] |
Ward S, Hepburn E, Li K, et al. Selective recruitment and retainment of regulatory T cells in human colorectal cancer. The Lancet, 2013, 381: S113.
|
[3] |
万德森.结直肠癌流行病学与预防.中国中西结合外科杂志,2011,17(1): 3-6.
|
[4] |
Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol, 2005, 5(4):331-342.
|
[5] |
Muller S, Scaffidi P, Degryse B, et al. New EMBO members′review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal. EMBO J, 2001, 20(16): 4337-4340.
|
[6] |
Dong Xda E, Ito N, Lotze MT, et al. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother, 2007, 30(6): 596-606.
|
[7] |
Ellerman JE, Brown CK, de Vera M, et al. Masquerader: high mobility group box-1 and cancer. Clin Cancer Res, 2007, 13(10): 2836-2848.
|
[8] |
Tang D, Kang R, Zeh HJ, et al. High-mobility group box 1 and cancer. Biochim Biophys Acta, 2010, 1799(1-2): 131-140.
|
[9] |
Moriwaka Y, Luo Y, Ohmori H, et al. HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer.Pathobiology, 2010, 77(1):17-23.
|
[10] |
Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med, 2007, 13(9): 1050-1059.
|
[11] |
Curtin JF, Liu N, Candolfi M, et al. HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med, 2009, 6(1): e10.
|
[12] |
Zeestraten EC, Benard A, Reimers MS, et al. The prognostic Value of the Apoptosis pathway in colorectal Cancer: A Review of the Literature on Biomarkers Identified by Immunohistochemistry. Biomarkers in cancer, 2013, 5: 13-29.
|
[13] |
易呈浩,葛维挺,黄彦钦,等.1368例结直肠癌TNM分期及预后分析.中国肿瘤临床,2012,39(9): 597-601.
|
[14] |
Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol, 2007, 81(1): 1-5.
|
[15] |
Mantovani A. Cancer: inflaming metastasis. Nature, 2009, 457(7225): 36-37.
|
[16] |
Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature, 2008, 454(7203): 436-444.
|
[17] |
Moriwaka Y, Luo Y, Ohmori H, et al. HMGB1 attenuates anti-metastatic defense of the lymph nodes in colorectal cancer. Pathobiology, 2010, 77(1): 17-23.
|
[18] |
何贤辉,欧阳东云.细胞自噬与高迁移率族蛋白B-1 (HMGB1)介导肿瘤耐药的研究进展.暨南大学学报(医学版),2011,32(2): 126-140.
|
[19] |
Scopa CD, Vagianos C, Kardamakis D, et al. bcl-2/bax ratio as a predictive marker for therapeutic response to radiotherapy in patients with rectal cancer. Appl Immunohistochem Mol Morphol, 2001, 9(4): 329-334.
|
[20] |
hodapasand E, Jafarzadeh N, Farrokhi F, et al. Is Bax/Bcl-2 ratio considered as a prognostic marker with age and tumor location in colorectal cancer? Iran Biomed J, 2015, 19(2): 69-75.
|